RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The...
RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The...
RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The U.S. Participating In The Study
RenovoRx宣布，位于纽约海德公园的Northwell Health癌症研究所正在招募局部晚期胰腺癌患者，参与公司的III期TiGeR-PaC临床试验；NHCI加入了美国各地参与该研究的著名临床地点。
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Northwell Health癌症研究所是最近加入TIGeR-PaC研究的临床地点，RenovoRx旨在于2025年上半年达到完全患者招募。
Phase III Clinical Trial is Evaluating the TAMP (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer
III期临床试验正在评估TAMP（经动脉微灌注）治疗平台用于治疗局部晚期胰腺癌。
LOS ALTOS, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, announced today that the Northwell Health Cancer Institute ("NHCI") in New Hyde Park, NY is enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. NHCI joins esteemed clinical sites throughout the United States participating in the study.
加利福尼亚州洛斯阿尔托斯，2024年11月20日（全球新闻通讯）—— RenovoRx, Inc.（"RenovoRx"或"公司"）（纳斯达克:RNXT），一家开发新型靶向肿瘤治疗并提供RenovoCath——一种新型的FDA批准的局部药物输送平台的生命科学公司，今天宣布，位于纽约海德公园的Northwell Health癌症研究所（"NHCI"）正在招募局部晚期胰腺癌（LAPC）患者，参与公司正在进行的关键III期TIGeR-PaC临床试验。NHCI加入了美国各地参与该研究的著名临床地点。
译文内容由第三方软件翻译。
